CD274 and neoplasm: PD-1/PD-L1 inhibitors restore the killing function of T cells against tumor cells by impeding the binding of PD-L1 on the surface of tumor cells to PD-1 on the surface of T cells, thereby enhancing anti-tumor immune responses.